Showing results (131-140 of 140) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 140 results.
Archives of Biochemistry and Biophysics|July 24, 1998
Induction of cytochrome P4503A by taxol in primary cultures of human hepatocytesV E Kostrubsky, L D Lewis, S C Strom, et al.
Schizophrenia Research|October 12, 2001
A longitudinal study of hippocampal volume in first episode psychosis and chronic schizophreniaS J Wood, D Velakoulis, D J Smith, et al.
Journal of Immunological Methods|February 27, 2001
Pharmacokinetic-pharmacodynamic relationships of the bispecific antibody MDX-H210 when administered in combination with interferon gamma: a multiple-dose phase-I study in patients with advanced cancer which overexpresses HER-2/neuL D Lewis, B F Cole, P K Wallace, et al.
Leukemia|August 24, 2007
Aplidin synergizes with cytosine arabinoside: functional relevance of mitochondria in Aplidin-induced cytotoxicityR Humeniuk, L G Menon, P J Mishra, et al.
Molecular Psychiatry|July 9, 2008
Brain surface contraction mapped in first-episode schizophrenia: a longitudinal magnetic resonance imaging studyD Sun, G W Stuart, M Jenkinson, et al.
International Journal of Radiation Oncology, Biology, Physics|August 3, 2001
Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreasJ M Pipas, S E Mitchell, R J Barth, et al.
Journal of Immunological Methods|February 27, 2001
Bispecific antibody-targeted phagocytosis of HER-2/neu expressing tumor cells by myeloid cells activated in vivoP K Wallace, P A Kaufman, L D Lewis, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 24, 2001
Phase I pilot trial of the bispecific antibody MDXH210 (anti-Fc gamma RI X anti-HER-2/neu) in patients whose prostate cancer overexpresses HER-2/neuT Schwaab, L D Lewis, B F Cole, et al.
Clinical Pharmacology and Therapeutics|October 1, 2010
An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumorsB C Goh, N J Reddy, U B Dandamudi, et al.
International Journal of Clinical Pharmacology and Therapeutics|March 14, 2009
Bioequivalence study of a new oral topotecan formulation, relative to the current topotecan formulation, in patients with advanced solid tumorsR L Oostendorp, J Loftiss, S Goel, et al.
Pageof 14